These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 20925231)

  • 1. [Guideline for prevention of RhD alloimmunization in RhD negative women].
    Lubuský M; Procházka M; Simetka O; Holusková I
    Ceska Gynekol; 2010 Aug; 75(4):323-4. PubMed ID: 20925231
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Guideline for prevention of RhD alloimmunizationin RhD negative women].
    Lubušký M; Procházka M; Simetka O; Holusková I
    Ceska Gynekol; 2013 Apr; 78(2):132-3. PubMed ID: 23710977
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevention of Rh alloimmunization.
    Fung Kee Fung K; Eason E; Crane J; Armson A; De La Ronde S; Farine D; Keenan-Lindsay L; Leduc L; Reid GJ; Aerde JV; Wilson RD; Davies G; Désilets VA; Summers A; Wyatt P; Young DC;
    J Obstet Gynaecol Can; 2003 Sep; 25(9):765-73. PubMed ID: 12970812
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Prevention of fetomaternal rhesus-D allo-immunization. Practical aspects].
    Cortey A; Brossard Y
    J Gynecol Obstet Biol Reprod (Paris); 2006 Feb; 35(1 Suppl):1S123-1S130. PubMed ID: 16495838
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Spontaneous antepartal RhD alloimmunization].
    Studničková M; Holusková I; Durdová V; Kratochvílová T; Strašilová P; Marková I; Lubušký M
    Ceska Gynekol; 2015 Dec; 80(6):401-4. PubMed ID: 26741153
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevention of RhD alloimmunization in RhD negative women.
    Lubusky M
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2010 Mar; 154(1):3-7. PubMed ID: 20445704
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The scientific basis of antenatal prophylaxis.
    Urbaniak SJ
    Br J Obstet Gynaecol; 1998 Nov; 105 Suppl 18():11-8. PubMed ID: 9863973
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Possibility to identify fetomaternal haemorrhage].
    Studnicková M; L'ubuský M; Ordeltová M; Procházka M
    Ceska Gynekol; 2010 Oct; 75(5):443-6. PubMed ID: 21374922
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Following targeted routine antenatal anti-D prophylaxis, almost half of the pregnant women had undetectable anti-D prophylaxis at delivery.
    Sørensen K; Stjern HE; Karlsen BAG; Tomter G; Ystad I; Herud I; Baevre MS; Llohn AH; Akkök ÇA
    Acta Obstet Gynecol Scand; 2022 Apr; 101(4):431-440. PubMed ID: 35224728
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intramuscular versus intravenous anti-D for preventing Rhesus alloimmunization during pregnancy.
    Okwundu CI; Afolabi BB
    Cochrane Database Syst Rev; 2013 Jan; (1):CD007885. PubMed ID: 23440818
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An audit of the investigation and use of anti-D immunoglobulin prophylaxis in Tayside.
    Rennie I; Smith A; Smith R; Rawlinson PS; Clark P
    Health Bull (Edinb); 2001 May; 59(3):150-4. PubMed ID: 12664753
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Consequences of being Rhesus D immunized during pregnancy and how to optimize new prevention strategies.
    Tiblad E; Westgren M; Pasupathy D; Karlsson A; Wikman AT
    Acta Obstet Gynecol Scand; 2013 Sep; 92(9):1079-85. PubMed ID: 23750781
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Prevention of fetomaternal rhesus-D allo-immunization. Perspectives].
    Cortey A; Brossard Y; Beliard R; Bourel D
    J Gynecol Obstet Biol Reprod (Paris); 2006 Feb; 35(1 Suppl):1S119-1S122. PubMed ID: 16495837
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Appropriate provision of anti-D prophylaxis to RhD negative pregnant women: a scoping review.
    Fyfe TM; Ritchey MJ; Taruc C; Crompton D; Galliford B; Perrin R
    BMC Pregnancy Childbirth; 2014 Dec; 14():411. PubMed ID: 25491600
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Prevention of Rh (D) alloimmunization in Rh (D) negative women in pregnancy and after birth of Rh (D) positive infant].
    L'ubuský M; Procházka M; Krejcová L; Vetr M; Santavý J; Kudela M
    Ceska Gynekol; 2006 May; 71(3):173-9. PubMed ID: 16768042
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Costs and clinical outcomes of noninvasive fetal RhD typing for targeted prophylaxis.
    Hawk AF; Chang EY; Shields SM; Simpson KN
    Obstet Gynecol; 2013 Sep; 122(3):579-85. PubMed ID: 23921866
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of first trimester non-invasive fetal RHD screening for targeted antenatal anti-D prophylaxis in RhD-negative pregnant women: a model-based analysis.
    Neovius M; Tiblad E; Westgren M; Kublickas M; Neovius K; Wikman A
    BJOG; 2016 Jul; 123(8):1337-46. PubMed ID: 26663771
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Costs and benefits of non-invasive fetal RhD determination.
    Teitelbaum L; Metcalfe A; Clarke G; Parboosingh JS; Wilson RD; Johnson JM
    Ultrasound Obstet Gynecol; 2015 Jan; 45(1):84-8. PubMed ID: 25380024
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk factors for RhD immunisation despite antenatal and postnatal anti-D prophylaxis.
    Koelewijn JM; de Haas M; Vrijkotte TG; van der Schoot CE; Bonsel GJ
    BJOG; 2009 Sep; 116(10):1307-14. PubMed ID: 19538414
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeted routine antenatal anti-D prophylaxis in the prevention of RhD immunisation--outcome of a new antenatal screening and prevention program.
    Tiblad E; Taune Wikman A; Ajne G; Blanck A; Jansson Y; Karlsson A; Nordlander E; Holländer BS; Westgren M
    PLoS One; 2013; 8(8):e70984. PubMed ID: 23940682
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.